EOFLOW

EOFlow Initiates Eco-Friendly Disposal Campaign for EOPatch in Korea Embracing and Integrating Environmental, Social, and Governance (ESG)

▶EOFlow will collect, process, and dispose of used EOPatch pumps in an environmentally safe manner ▶EOFlow will set up an Incentive Program for this Campaign EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced today that the Company is initiating an environmentally friendly disposal campaign to minimize the impact of used EOPatch pumps on the environment. As there are no environmental regulations or guidelines for proper disposal of used medical devices in Korea, used patc...

Nov. 09. 2021
EOFlow to Raise 100 Billion Korean Won and Offer Stock Split Capital Raised Will Be Used For Global Market Expansion

▶ 100 billion Won to be raised with new common stock offering, to be followed by a 2:1 stock split EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will raise some 100 billion Won with new common stock offering, after which it will do a 2:1 stock split. The Company will make a new public offering of its common stocks. The company will issue up to 3,000,000 shares of common stocks, representing 25.99% of the current total number of issued shares. The...

Oct. 28. 2021
EOFlow and Sinocare Establish a Joint Venture Company

▶ Sinocare is China’s Largest Diabetes Management Instrument Manufacturer ▶ Joint venture company to launch a full-scale effort for clinical study to obtain regulatory approval for EOPatch manufacturing and distribution in China ▶ High growth expected from EOPatch business in China where world’s largest diabetes population live EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company will establish a joint venture company “SINOFLOW Co., Ltd...

Oct. 27. 2021
EOFlow Begins Clinical Study of its Wearable Insulin Pump “EOPatch” on People With Type 2 diabetes in Korea

▶ This clinical study involves ten leading university hospitals and up to one hundred and thirty-six people with Type 2 diabetes. It is Korea’s largest ever clinical study employing insulin pumps. ▶ This pioneering study aims to demonstrate and validate efficacy of EOPatch for Type 2 diabetes therapy. EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that the Company completed enrollment of first patient in a clinical study on type 2 diabetes for its wearable in...

Oct. 14. 2021
EOFlow Completes its First Shipment to Europe

▶ EOFlow’s European exclusive distributing partner Menarini to showcase the EOPatch at EASD 2021 EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has made its first shipment to Europe today. After launching the wearable insulin pump in Korea this March and obtaining the CE certification in May, EOFlow is now expanding its reach to Europe, starting with the first shipment completed on September 30. EOFlow officially launched its EOPatch, Korea’s first (and the w...

Sep. 30. 2021
President Malave interviews a major newspaper in Korea

Luis Malave, the president of EOFLOW, visited Korea recently and had an interview with one of the major Korean newspapers. Here is the link to the article, in Korean only: http://news.naver.com/main/read.nhn?mode=LSD&mid=sec&oid=015&aid=0003925789&sid1=001

Apr. 26. 2018
EOFLOW awarded a government grant to develop automatic insulin delivery system

EOFLOW is awarded a government R&D grant for developing a wearable disposable automatic insulin delivery system that functionally integrates a continuous glucose sensor and a wearable insulin pump to provide highly automated blood glucose control service with little or no user attention. "This award, together with the recent award from JDRF (Juvenile Diabetes Research Foundation) and the licensing of the highly proven closed-loop algorithm from Typezero, will bring us one step closer to a successful launch of ...

Apr. 16. 2018
EOFLOW in a newspaper article

The Investor, a startup-centric English news service run by a highly respected Korean English newspaper, Korea Herald, recently covered an article on EOFLOW: http://www.theinvestor.co.kr/view.php?ud=20180405000593

Apr. 13. 2018
Dr. Ian Welsford joins EOFLOW as a new Chief Compliance Officer

Dr. Ian Welsford, a long-time industry insider who has seen the emergence of the smart insulin patch pump industry, has joined EOFLOW as the new Chief Compliance Officer. Dr. Welsford brings to EOFlow over 25 years of experience in Quality Assurance, Regulatory and Clinical Affairs working primarily in the medical device industry with an emphasis on electromechanical systems including insulin pumps (external and implantable), closed loop blood glucose control (a.k.a. artificial pancreas) systems, in vitro diagnostic syst...

Apr. 09. 2018
TypeZero and EOFlow to Develop Closed Loop System Featuring AP Technology and Patch Insulin Pump

CHARLOTTESVILLE, Va. and SEOUL, South Korea – Digital health company TypeZero Technologies, Inc. and medical device manufacturer EOFlow Co., LTD today announced the companies have completed a license agreement to implement TypeZero’s closed loop technology alongside EOFlow’s patch insulin pump. The non-exclusive agreement allows for development of a closed loop product that can be commercialized throughout Asia. EOFlow’s EOPatch system features a disposable patch insulin pump that is among the smallest and lightes...

Feb. 14. 2018
EOFLOW gets media coverage around the globe

With the recent joint announcement between JDRF (Juvenile Diabetes Research Fund) and EOFLOW, the company and its wearable insulin patch pump product, EOPatch, are getting some attention. Check out the links below: From MobiHealthNews: 'JDRF backs EOPatch, a tiny, wearable insulin pump' http://www.mobihealthnews.com/content/jdrf-backs-eopatch-tiny-wearable-insulin-pump From MD+DI newsletter (Qmed): 'How Two Tiny Insulin Devices Won JDRF Support' https://www.mddionline.com/how-two-tiny-insulin-devices-won-jdrf-support Fr...

Feb. 06. 2018
EOFLOW covered in a major newspaper article

Maeil Business News Korea (www.mk.co.kr), one of the most widely read economics newspapers in Korea, runs an article on EOFLOW and its wearable automated insulin infusion system (AKA artificial pancreas) development support by JDRF (Juvenile Diabetes Research Fund). To read the Korean article, click the link below: http://news.mk.co.kr/newsRead.php?year=2018&no=63532

Jan. 29. 2018
JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes

JDRF Partners with EOFlow to Develop Wearable Automated Insulin Delivery System for People with Type 1 Diabetes —The disposable patch device would be small enough to enable use of wearable artificial pancreas technology on a child— NEW YORK, USA and SEOUL, South Korea, January 25, 2017 — JDRF, the global leading organization funding type 1 diabetes (T1D) research, is pleased to announce a new Industry Development and Discovery Partnership supporting South Korea’s EOFlow Co., Ltd. in the development of a wearable, d...

Jan. 28. 2018
EOFLOW chosen as the best TIPS company of 2017

EOFLOW was voted the best TIPS-backed company of 2017 at the '2017 TIPS Grand Convention.' The selection was based on weighed scores of votes from a group of investors as well as the convention attendees. TIPS (Tech Incubator Program for Start-up) is a startup incubation program sponsored by Ministry of SME and Startups (MSS), and jointly run by Korea Business Angels Association, private angels & incubator groups. TIPS has been widely considered the best-run incubation program in Korea that it is bei...

Dec. 21. 2017
EOPatch gets its first regulatory approval

EOPatch, the first wearable disposable insulin pump product from EOFLOW, got its first regulatory approval, from the Korean MFDS (Ministry of Food and Drug Safety). EOFLOW will immediately start preceding clinical trials and plans to launch the product in Korea this coming spring. Earlier, EOFLOW has appointed Huons (www.huons.com) as the exclusive distributor of EOPatch in the Korean market.

Dec. 18. 2017

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here